tetano
Editor, Senior Moderator
Front Med (Lausanne)
. 2020 Oct 14;7:580677.
doi: 10.3389/fmed.2020.580677. eCollection 2020.
Frequencies of CD33+CD11b+HLA-DR-CD14-CD66b+ and CD33+CD11b+HLA-DR-CD14+CD66b- Cells in Peripheral Blood as Severity Immune Biomarkers in COVID-19
Ricardo Wesley Alberca[SUP] 1 [/SUP], Milena Mary de Souza Andrade[SUP] 1 [/SUP], Anna Cl?udia Calvielli Castelo Branco[SUP] 1 2 [/SUP], Anna Julia Pietrobon[SUP] 1 2 [/SUP], N?talli Zanete Pereira[SUP] 1 [/SUP], Iara Grigoletto Fernandes[SUP] 1 [/SUP], Luana de Mendon?a Oliveira[SUP] 1 2 [/SUP], Franciane Mouradian Emidio Teixeira[SUP] 1 2 [/SUP], Danielle Rosa Beserra[SUP] 1 [/SUP], Emily Araujo de Oliveira[SUP] 1 [/SUP], Sarah Cristina Gozzi-Silva[SUP] 2 [/SUP], Yasmim ?lefe Leuzzi Ramos[SUP] 1 [/SUP], Cyro Alves de Brito[SUP] 3 [/SUP], Marcelo Arnone[SUP] 4 [/SUP], Raquel Leao Orfali[SUP] 1 [/SUP], Valeria Aoki[SUP] 1 [/SUP], Alberto Jose da Silva Duarte[SUP] 5 [/SUP], Maria Notomi Sato[SUP] 1 [/SUP]
Affiliations
Abstract
Common clinical features of patients with Coronavirus disease-2019 (COVID-19) vary from fever, to acute severe respiratory distress syndrome. Several laboratory parameters are reported as indicators of COVID-19 severity. We hereby describe the possible novel severity biomarkers for COVID-19, CD11b+CD33+HLA-DR-CD14+ cells and CD11b+CD33+HLA-DR-CD66b+ cells.
Keywords: COVID-19; SARS-CoV-2; biomarker; infection; severity.
. 2020 Oct 14;7:580677.
doi: 10.3389/fmed.2020.580677. eCollection 2020.
Frequencies of CD33+CD11b+HLA-DR-CD14-CD66b+ and CD33+CD11b+HLA-DR-CD14+CD66b- Cells in Peripheral Blood as Severity Immune Biomarkers in COVID-19
Ricardo Wesley Alberca[SUP] 1 [/SUP], Milena Mary de Souza Andrade[SUP] 1 [/SUP], Anna Cl?udia Calvielli Castelo Branco[SUP] 1 2 [/SUP], Anna Julia Pietrobon[SUP] 1 2 [/SUP], N?talli Zanete Pereira[SUP] 1 [/SUP], Iara Grigoletto Fernandes[SUP] 1 [/SUP], Luana de Mendon?a Oliveira[SUP] 1 2 [/SUP], Franciane Mouradian Emidio Teixeira[SUP] 1 2 [/SUP], Danielle Rosa Beserra[SUP] 1 [/SUP], Emily Araujo de Oliveira[SUP] 1 [/SUP], Sarah Cristina Gozzi-Silva[SUP] 2 [/SUP], Yasmim ?lefe Leuzzi Ramos[SUP] 1 [/SUP], Cyro Alves de Brito[SUP] 3 [/SUP], Marcelo Arnone[SUP] 4 [/SUP], Raquel Leao Orfali[SUP] 1 [/SUP], Valeria Aoki[SUP] 1 [/SUP], Alberto Jose da Silva Duarte[SUP] 5 [/SUP], Maria Notomi Sato[SUP] 1 [/SUP]
Affiliations
- PMID: 33178720
- PMCID: PMC7592395
- DOI: 10.3389/fmed.2020.580677
Abstract
Common clinical features of patients with Coronavirus disease-2019 (COVID-19) vary from fever, to acute severe respiratory distress syndrome. Several laboratory parameters are reported as indicators of COVID-19 severity. We hereby describe the possible novel severity biomarkers for COVID-19, CD11b+CD33+HLA-DR-CD14+ cells and CD11b+CD33+HLA-DR-CD66b+ cells.
Keywords: COVID-19; SARS-CoV-2; biomarker; infection; severity.